
|Articles|October 1, 2002
Developing neuroprotective drugs for glaucoma no easy task
Neuroprotection is a concept that originated in the CNS community with the development of therapies aimed at preventing or retarding the manifestations of disorders such as Parkinson's and Alzheimer's diseases, stroke, and head trauma. Less than 15 years ago, the ophthalmic community began to discuss this concept as a novel way to preserve vision in disorders of the retina.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
PainReform launches development plan for OcuRing-K, readies phase 2 trial
4
Phase 1 trial findings confirm safety and tolerability of Huons’ dry eye therapy
5















































.png)


